473
PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
L. Adèsa, J. Wattsb, A. Radinoffc, M.A. Sangermand, M. Cerranoe, P.F. Lopezf, J. Zeidnerg, M.D. Campeloh, C. Grauxi, J. Liesveldj, D. Selleslagk, N. Tzvetkovl, R.J. Framm, D. Zhaom, J. Bellm, S. Friedlanderm, D.V. Fallerm, M.A. Sekeresn
a Hôpital Saint-Louis, Paris, France
b Sylvester Comprehensive Cancer Center, University of Miami, Miami, United States
c University Hospital Sveti Ivan Rislki, Sofia, Bulgaria
d Institut Català d’Oncologia-Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain
e Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy
f Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
g University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, United States
h Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
i Université Catholique de Louvain, Centre Hospitalier Universitaire, Namur, Yvoir, Belgium
j The James P Wilmot Cancer Institute, University of Rochester, Rochester, United States
k AZ Sint Jan Brugge-Oostende, Brugge, Belgium
l MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria
m Millennium Pharmaceuticals, Inc., Cambridge, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
n Cleveland Clinic, Cleveland, United States
Ver másLido
3077
Vezesque se leu este artigo
1179
Total PDF
1898
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 69 | 13 | 82 |
| 2025 9 | 96 | 15 | 111 |
| 2025 8 | 52 | 15 | 67 |
| 2025 7 | 80 | 33 | 113 |
| 2025 6 | 60 | 15 | 75 |
| 2025 5 | 59 | 14 | 73 |
| 2025 4 | 46 | 13 | 59 |
| 2025 3 | 69 | 9 | 78 |
| 2025 2 | 47 | 19 | 66 |
| 2025 1 | 54 | 17 | 71 |
| 2024 12 | 38 | 15 | 53 |
| 2024 11 | 45 | 15 | 60 |
| 2024 10 | 24 | 16 | 40 |
| 2024 9 | 46 | 17 | 63 |
| 2024 8 | 28 | 19 | 47 |
| 2024 7 | 22 | 21 | 43 |
| 2024 6 | 27 | 16 | 43 |
| 2024 5 | 30 | 28 | 58 |
| 2024 4 | 36 | 16 | 52 |
| 2024 3 | 33 | 13 | 46 |
| 2024 2 | 32 | 23 | 55 |
| 2024 1 | 26 | 14 | 40 |
| 2023 12 | 21 | 29 | 50 |
| 2023 11 | 38 | 19 | 57 |
| 2023 10 | 20 | 25 | 45 |
| 2023 9 | 31 | 27 | 58 |
| 2023 8 | 34 | 18 | 52 |
| 2023 7 | 28 | 10 | 38 |
| 2023 6 | 25 | 21 | 46 |
| 2023 5 | 31 | 20 | 51 |
| 2023 4 | 16 | 6 | 22 |
| 2023 3 | 27 | 16 | 43 |
| 2023 2 | 24 | 11 | 35 |
| 2023 1 | 19 | 6 | 25 |
| 2022 12 | 27 | 18 | 45 |
| 2022 11 | 26 | 23 | 49 |
| 2022 10 | 27 | 24 | 51 |
| 2022 9 | 31 | 32 | 63 |
| 2022 8 | 20 | 13 | 33 |
| 2022 7 | 24 | 27 | 51 |
| 2022 6 | 19 | 21 | 40 |
| 2022 5 | 12 | 25 | 37 |
| 2022 4 | 23 | 22 | 45 |
| 2022 3 | 15 | 18 | 33 |
| 2022 2 | 19 | 21 | 40 |
| 2021 1 | 17 | 22 | 39 |
| 2021 12 | 16 | 19 | 35 |
| 2021 11 | 19 | 27 | 46 |
| 2021 10 | 31 | 33 | 64 |
| 2021 9 | 25 | 26 | 51 |
| 2021 8 | 32 | 29 | 61 |
| 2021 7 | 20 | 20 | 40 |
| 2021 6 | 16 | 25 | 41 |
| 2021 5 | 19 | 39 | 58 |
| 2021 4 | 40 | 28 | 68 |
| 2021 3 | 22 | 19 | 41 |
| 2021 2 | 17 | 11 | 28 |
| 2020 1 | 10 | 19 | 29 |
| 2020 12 | 21 | 17 | 38 |
| 2020 11 | 17 | 17 | 34 |
Mostrar tudo
